While there is no data available regarding the effect of therapies targeting VEGF-D in HF, PH, and PH-LHD patients, early treatment with VEGFR3 inhibitors has been shown to improve the lumen obliteration and pulmonary pressures in Sugen/hypoxia rat models of PAH (76). This evidence concerns the gene VEGFD and hydrops fetalis.